Cellebrite DI (NASDAQ:CLBT) Sets New 1-Year High at $14.14

Cellebrite DI Ltd. (NASDAQ:CLBT)’s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $14.14 and last traded at $14.14, with a volume of 1546 shares changing hands. The stock had previously closed at $13.98.

Analyst Ratings Changes

Several equities research analysts recently issued reports on CLBT shares. JPMorgan Chase & Co. upped their price target on Cellebrite DI from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, May 24th. Lake Street Capital started coverage on shares of Cellebrite DI in a report on Friday, April 19th. They issued a “buy” rating and a $13.00 target price for the company. Bank of America boosted their price target on shares of Cellebrite DI from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Craig Hallum upped their price objective on shares of Cellebrite DI from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Finally, Needham & Company LLC lifted their target price on shares of Cellebrite DI from $13.50 to $14.00 and gave the stock a “buy” rating in a research report on Friday, May 24th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $13.17.

Cellebrite DI Price Performance

The firm has a market cap of $2.89 billion, a PE ratio of -24.10, a P/E/G ratio of 1.90 and a beta of 1.50. The business’s fifty day moving average is $11.87 and its 200-day moving average is $11.06.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, May 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Cellebrite DI had a negative net margin of 32.57% and a positive return on equity of 417.94%. The firm had revenue of $89.60 million during the quarter, compared to the consensus estimate of $85.34 million. During the same period in the prior year, the firm earned $0.03 EPS. The company’s revenue was up 25.8% compared to the same quarter last year. Analysts forecast that Cellebrite DI Ltd. will post 0.34 EPS for the current year.

Institutional Trading of Cellebrite DI

Several hedge funds have recently made changes to their positions in CLBT. Parallel Advisors LLC increased its holdings in Cellebrite DI by 75.0% in the 4th quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock worth $30,000 after acquiring an additional 1,500 shares during the last quarter. Quarry LP bought a new stake in shares of Cellebrite DI during the 4th quarter valued at $36,000. Central Asset Investments & Management Holdings HK Ltd bought a new stake in shares of Cellebrite DI during the 4th quarter valued at $113,000. Hennessy Advisors Inc. purchased a new stake in Cellebrite DI during the 4th quarter worth about $131,000. Finally, Russell Investments Group Ltd. boosted its stake in Cellebrite DI by 92.5% in the 1st quarter. Russell Investments Group Ltd. now owns 16,649 shares of the company’s stock worth $188,000 after purchasing an additional 8,001 shares during the period. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.